Bell, David J., Wootton, Daniel G., Mukaka, Mavuto, Montgomery, Jacqui, Kayange, Noel, Chimpeni, Phillips, Hughes, Dyfrig, Molyneux, Malcolm E., Ward, Steve A., Winstanley, Peter and Lalloo, David G.. (2009) Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi. Malaria Journal, Vol.8 (No.204). ISSN 1475-2875

Preview

PDF WRAP_Winstanley_1475-2875-8-204.pdf - Published Version - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader Download (325Kb)

Abstract

Sulphadoxine-pyrimethamine (SP) is the only single dose therapy for uncomplicated malaria, but there is widespread resistance. At the time of this study, artemether-lumefantrine (AL) and chlorproguanil-dapsone (CPD), both multi-dose regimes, were considered possible alternatives to SP in Malawi. The aim of this study was to investigate the impact of poor adherence on the effectiveness of AL and CPD.

Item Type:	Journal Article
Subjects:	R Medicine > RA Public aspects of medicine
Divisions:	Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH):	Malaria -- Treatment -- Malawi
Journal or Publication Title:	Malaria Journal
Publisher:	BioMed Central Ltd.
ISSN:	1475-2875
Date:	29 August 2009
Volume:	Vol.8
Number:	No.204
Identification Number:	10.1186/1475-2875-8-204
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Open Access
Funder:	Great Britain. Dept. for International Development
Grant number:	RES 8074 (DID)
References:	1. Sulo J, Chimpeni P, Hatcher J, Kublin JG, Plowe CV, Molyneux ME, Marsh K, Taylor TE, Watkins WM, Winstanley PA: Chlorproguanildapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial. Lancet 2002, 360:1136-1143. 2. Press Release on Lapdap [http://www.gsk.com/media/pressre leases/2008/2008_pressrelease_0014.htm] 3. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria [http:// www.who.int/malaria/docs/ProtocolWHO.pdf] 4. Lindegardh N, Annerberg A, Blessborn D, Bergqvist Y, Day N, White NJ: Development and validation of a bioanalytical method using automated solid-phase extraction and LC-UV for the simultaneous determination of lumefantrine and its desbutyl metabolite in plasma. J Pharm Biomed Anal 2005, 37:1081-1088. 5. Price RN, Uhlemann AC, van VM, Brockman A, Hutagalung R, Nair S, Nash D, Singhasivanon P, Anderson TJ, Krishna S, White NJ, Nosten F: Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrugresistant Plasmodium falciparum malaria. Clin Infect Dis 2006, 42:1570-1577. 6. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, Christian J, Maldonado T, Duran D, Kaplan AH, Wenger NS: A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001, 134:968-977. 7. World Malaria Report 2008 [http://www.who.int/malaria/ wmr2008/] 8. Garber MC, Nau DP, Erickson SR, Aikens JE, Lawrence JB: The concordance of self-report with other measures of medication adherence: a summary of the literature. Med Care 2004, 42:649-652. 9. Bell DJ, Kapitao Y, Sikwese R, van Oosterhout JJ, Lalloo DG: Adherence to antiretroviral therapy in patients receiving free treatment from a government hospital in Blantyre, Malawi. J Acquir Immune Defic Syndr 2007, 45:560-563. 10. Rahman MM, Dondorp AM, Day NP, Lindegardh N, Imwong M, Faiz MA, Bangali AM, Kamal AT, Karim J, Kaewkungwal J, Singhasivanon P: Adherence and efficacy of supervised versus non-supervised treatment with artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Bangladesh: a randomised controlled trial. Trans R Soc Trop Med Hyg 2008, 102:861-867. 11. Ajayi IO, Browne EN, Bateganya F, Yar D, Happi C, Falade CO, Gbotosho GO, Yusuf B, Boateng S, Mugittu K, Cousens S, Nanyunja M, Pagnoni F: Effectiveness of artemisinin-based combination therapy used in the context of home management of malaria: a report from three study sites in sub-Saharan Africa. Malar J 2008, 7:190. 12. Fogg C, Bajunirwe F, Piola P, Biraro S, Checchi F, Kiguli J, Namiiro P, Musabe J, Kyomugisha A, Guthmann JP: Adherence to a six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda. Am J Trop Med Hyg 2004, 71:525-530. 13. White NJ, Stepniewska K, Barnes K, Price RN, Simpson J: Simplified antimalarial therapeutic monitoring: using the day-7 drug level? Trends Parasitol 2008, 24:159-163. 14. Adjei GO, Kurtzhals JA, Rodrigues OP, Alifrangis M, Hoegberg LC, Kitcher ED, Badoe EV, Lamptey R, Goka BQ: Amodiaquineartesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. Malar J 2008, 7:127. 15. Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E, Babigumira J, Kigozi I, Kiguli J, Kyomuhendo J, Ferradini L, Taylor W, Checchi F, Guthmann JP: Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. Lancet 2005, 365:1467-1473. 16. Sagara I, Diallo A, Kone M, Coulibaly M, Diawara SI, Guindo O, Maiga H, Niambele MB, Sissoko M, Dicko A, Djimde A, Doumbo OK: A randomized trial of artesunate-mefloquine versus artemether- lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali. Am J Trop Med Hyg 2008, 79:655-661. 17. Urquhart J: Pharmacodynamics of variable patient compliance: implications for pharmaceutical value. Adv Drug Deliv Rev 1998, 33:207-219.
URI:	http://wrap.warwick.ac.uk/id/eprint/36484

Request changes to a record

Actions (login required)

View Item